The PRISM 2 project builds on the results of PRISM and aims to further integrate quantitative biological approaches into clinical practice to improve the diagnosis and treatment of neuropsychiatric diseases.
PRISM 2 outcomes are expected to have a positive impact on public health in general by improving European citizens’ mental health and well-being, reducing the stigma of neuropsychiatric disorders, and advancing health technology assessment, clinical practice, and regulatory guidelines. In addition, PRISM 2 will improve the drug discovery and development process by identifying and valorising novel biomarkers and potential drug targets, maximise the public-private partnership value by harnessing support from different stakeholders, and contribute to industrial prosperity and leadership of the European Union (EU), including small and medium-sized enterprises (SMEs).
